SCHEMBL6999539

SCHEMBL6999539

CCOC(=O)c1c(Nc2ccc(Cl)cc2[N+](=O)[O-])sc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.47
LMNA P02545 4/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
KMT2A Q03164 2/20 0.44
MAPK1 P28482 2/20 0.44
MEN1 O00255 1/20 0.44
CMA1 P23946 1/20 0.43
NR2F2 P24468 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PKM P14618 2/20 0.42
ALDH1A1 P00352 4/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
APP P05067 1/20 0.42
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6987733 0.92 L3MBTL1 (0.46) MAPTLMNANPSR1TDP1L3MBTL1
SCHEMBL6992000 0.90 KMT2A (0.44) MAPTLMNAKMT2AMAPK1SMN1; SMN2
SCHEMBL6995614 0.89 MAPT (0.42) MAPTLMNANPSR1TDP1KMT2A
SCHEMBL6994728 0.89 KMT2A (0.43) MAPTLMNATDP1L3MBTL1KMT2A
SCHEMBL6993538 0.89 KMT2A (0.43) MAPTLMNANPSR1TDP1L3MBTL1
SCHEMBL6990179 0.88 MAPT (0.46) MAPTLMNATDP1L3MBTL1KMT2A
SCHEMBL6996538 0.88 MAPT (0.50) MAPTLMNAKMT2AMAPK1MEN1
SCHEMBL6998467 0.86 MAPK1 (0.47) MAPTLMNANPSR1L3MBTL1KMT2A
SCHEMBL6991878 0.85 KMT2A (0.41) MAPTLMNANPSR1KMT2AMEN1
SCHEMBL7000921 0.84 MAPT (0.47) MAPTLMNANPSR1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885LMNA 4763/4885NPSR1 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.